Here is the design of a clinical trial:

Official Title: The BFF Study- The Better to Fix or Fuse Study 'Retaining or Removing the Joint in the Foot: A Randomized Controlled Multicenter Trial of Primary Arthrodesis Versus Joint Stabilisation in Lisfranc Fracture Dislocation Midfoot Injuries

Included conditions:
- Lisfranc Fracture
- Arthrodesis
- Internal Fixation
- Quality of Life

Study Armgroups:
- {'label': 'Patients enrolled in the ORIF group', 'type': 'ACTIVE_COMPARATOR', 'description': 'Open reduction and internal fixation (ORIF), ORIF will be done by using bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS). For fixation, TMT4 and/or TMT5 K-wires (1.6 or 2.0mm) can be used instead.', 'interventionNames': ['Procedure: Surgery']}
- {'label': 'Patients enrolled in the PA group', 'type': 'ACTIVE_COMPARATOR', 'description': 'PA will be done by removal of the articular surface and subsequent stabilization with bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS).', 'interventionNames': ['Procedure: Surgery']}

Interventions:
- {'type': 'PROCEDURE', 'name': 'Surgery', 'description': 'ORIF will be done by using bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS). For fixation TMT4 and/or TMT5 K-wires (1.6 or 2.0mm) can be used instead.\n\nPA will be done by removal of articular surface and subsequent stabilization with bridge plate (variable angle locking plate and/or locking plate and/or dynamic compression plate - 3.5mm, 2.7mm or 2.4mm) and/or transarticular screw osteosynthesis (4.0mm cannulated screws and/or solid small fragment screws and/or HCS).\n\nType and sequence of fixation of the involved rays as needed, partial or complete fixation as needed, judgement by treating surgeon.', 'armGroupLabels': ['Patients enrolled in the ORIF group', 'Patients enrolled in the PA group']}

Primary Outcomes:
- {'measure': 'The 5 level EQ-5D version (EQ-5d-5L) questionnaire', 'description': 'This validated questionnaire (as defined by the EQ-5D-5L questionnaire) is a descriptive system for health-related quality of life states in adults, consisting of five dimensions (Mobility, Self-care, Usual activities, Pain \\& discomfort, Anxiety \\& depression), each of which has five severity levels that are described by statements appropriate to that dimension. When the patients has no problems at the dimension, f.e. mobility, this is coded as "1".\n\nLEVEL 1: indicating no problem LEVEL 2: indicating slight problems LEVEL 3: indicating moderate problems LEVEL 4: indicating severe problems LEVEL 5: indicating unable to/extreme problems', 'timeFrame': '2-year follow up period'}

Please estimate the sample size based on the assumption: 
Significance level not explicitly stated, power of 80%, and consideration of near-perfect correlation in longitudinal analysis.
Sample size and feasibility
        The primary outcome is quality of life over the follow up period, quantified using the EQ-5D-5L score. The longitudinal analysis will include multiple observations per patient, but it is unclear how strong consecutive measurements are correlated. For that reason, we performed a sample size calculation for a cross-sectional contrast between the two groups, so that even with near-perfect correlation, we would have sufficient power to detect a clinically meaningful difference.
        The estimated standard deviation (SD) of the EQ-5D-5L scores is 0.15. To be able to have sufficient statistical power (i.e., 80%) to detect a clinically meaningful difference in QoL of 0.08 points, we need to include 56 patients per group, or 112 in total. We estimate, based on previous experience, that we would need to screen approximately 190 patients to find 112 patients eligible and willing to participate.